The U.S. issued additional FDA priority review vouchers for pediatric rare disease indications, keeping the pediatric PRV count near a recent record. Coverage noted that three new U.S. pediatric PRVs were issued since August, with the total one shy of the 11 granted in 2023. The report linked the voucher environment to falling fees and a sharp increase in the price of pediatric PRVs. The changing market signals how investors price the ability to obtain faster FDA review for qualifying pediatric development programs. For sponsors, pediatric PRVs can materially impact capital allocation and development timelines, since vouchers are often monetized or used to accelerate future review strategies.